StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) stock

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$35.91−0.53 (-1.45%)

Close on Nov 17, 2026Market cap $1.23BP/E –Yield –

Nektar Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Nektar Therapeutics's operating margin for the twelve months ending Dec 31, 2025 was -253.7%. For fiscal 2025 it was -253.7%, against -106.9% the year before. The highest annual figure on record is 57.6% in fiscal 2018.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-253.7%−146.8
FY2024Dec 31, 2024-106.9%+185.7
FY2023Dec 31, 2023-292.6%+116.0
FY2022Dec 31, 2022-408.6%+29.1
FY2021Dec 31, 2021-437.8%−159.8
FY2020Dec 31, 2020-278.0%+105.9
FY2019Dec 31, 2019-383.9%−441.6
FY2018Dec 31, 201857.6%+77.0
FY2017Dec 31, 2017-19.4%+48.8
FY2016Dec 31, 2016-68.2%−55.5
FY2015Dec 31, 2015-12.7%−4.5
FY2014Dec 31, 2014-8.2%+72.5
FY2013Dec 31, 2013-80.7%+93.2
FY2012Dec 31, 2012-173.9%−0.5
FY2011Dec 31, 2011-173.4%−155.6
FY2010Dec 31, 2010-17.8%+114.5
FY2009Dec 31, 2009-132.3%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2025Dec 31, 2025-126.9%−176.0
Q3 FY2025Sep 30, 2025-268.6%−126.3
Q2 FY2025Jun 30, 2025-324.2%−112.3
Q1 FY2025Mar 31, 2025-425.8%−262.0
Q4 FY2024Dec 31, 202449.2%+189.5
Q3 FY2024Sep 30, 2024-142.4%+43.4
Q2 FY2024Jun 30, 2024-211.9%+34.9
Q1 FY2024Mar 31, 2024-163.7%+460.1
Q4 FY2023Dec 31, 2023-140.3%+97.9
Q3 FY2023Sep 30, 2023-185.8%+44.0
Q2 FY2023Jun 30, 2023-246.8%+461.2
Q1 FY2023Mar 31, 2023-623.8%−154.2
Q4 FY2022Dec 31, 2022-238.2%+213.2
Q3 FY2022Sep 30, 2022-229.8%+226.0
Q2 FY2022Jun 30, 2022-708.1%−319.1
Q1 FY2022Mar 31, 2022-469.6%−7.0
Q4 FY2021Dec 31, 2021-451.5%+20.4
Q3 FY2021Sep 30, 2021-455.8%−112.7
Q2 FY2021Jun 30, 2021-389.0%−229.9
Q1 FY2021Mar 31, 2021-462.6%−198.4
Q4 FY2020Dec 31, 2020-471.9%−148.1
Q3 FY2020Sep 30, 2020-343.1%−5.2
Q2 FY2020Jun 30, 2020-159.1%+316.9
Q1 FY2020Mar 31, 2020-264.2%+163.4
Q4 FY2019Dec 31, 2019-323.8%−71.9
Q3 FY2019Sep 30, 2019-337.9%+17.3
Q2 FY2019Jun 30, 2019-476.0%−565.5
Q1 FY2019Mar 31, 2019-427.6%−199.5
Q4 FY2018Dec 31, 2018-251.8%−226.7
Q3 FY2018Sep 30, 2018-355.3%−400.7
Q2 FY2018Jun 30, 201889.5%+236.0
Q1 FY2018Mar 31, 2018-228.2%−8.0
Q4 FY2017Dec 31, 2017-25.2%+60.7
Q3 FY2017Sep 30, 201745.4%+136.0
Q2 FY2017Jun 30, 2017-146.5%−29.5
Q1 FY2017Mar 31, 2017-220.1%–
Q4 FY2016Dec 31, 2016-85.8%–
Q3 FY2016Sep 30, 2016-90.5%–
Q2 FY2016Jun 30, 2016-117.0%–

More Nektar Therapeutics figures

See a number that looks wrong?